Mon 7/16/2018 03:03 ET
DJIA25019.4194.520.38%TELCO159.911.140.71%GOLD1243.902.740.22%Shanghai2811.1619.960.71%
S&P 5002801.313.080.11%BANKS458.764.450.97%OIL69.230.721.04%BITCOIN6379.8015.310.24%
NASDAQ7825.982.350.03%PHARM521.281.510.29%US/EU1.170.000.26%Futures2804.506.000.21%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Aviron - AVIR   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add AVIR
  
From: Mores (Rep: 3)Date: 01/12/2018 13:40
Forum: Aviron - Msg #137Thread #673982117 (Rec: 0)
The transaction maximizes the value of Aviragen: Based on the valuations of a selected set of publicly traded vaccine companies, Vaxart’s estimated potential valuation prior to the merger is approximately $158 million. Based on the ownership structure in the transaction, this would imply a value of the combined company at $264 million, with the potential value of Aviragen in the merger being $106 million, a significant improvement in value compared to Aviragen’s current market capitalization of approximately $23 millioni.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser Mores: Reward | Watch | IgnoreAVIR: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add AVIR
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.